Stay updated on Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page update shows a revision from v3.4.1 to v3.4.2. No substantive changes to study content or key details such as eligibility criteria or outcomes are evident.
    Difference
    0.1%
    Check dated 2026-02-13T01:13:39.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Revision: v3.4.1 was added and v3.4.0 removed; this appears to be a version-label update with no substantive changes to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-05T12:25:07.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    Added Assuntina Sacco, MD as a study contact and removed Ezra Cohen, MD; updated QC status to 'Last Update Submitted that Met QC Criteria' with revision to v3.4.0. Introduced a new Show glossary option and updated metadata entries including 2026-01-28, 2026-01-26, and No FEAR Act Data.
    Difference
    0.5%
    Check dated 2026-01-29T06:24:16.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    A minor revision update is shown: Revision: v3.3.4 has been added (replacing v3.3.3), and it does not affect substantive content on the study page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T02:46:34.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    Added a dedicated Locations section with California as a listed study site, clarifying where the trial is conducted. Removed the older California Locations label and the HHS Vulnerability Disclosure link as part of the prior revision.
    Difference
    0.2%
    Check dated 2025-12-24T11:56:01.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    The terms 'Head and neck squamous cell carcinoma' and the related topic 'MedlinePlus Genetics' have been removed from the page.
    Difference
    0.2%
    Check dated 2025-12-02T17:23:39.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.